Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
Authors:
Open Access
- 6 March 2020
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 11 (4) , 1029-1043
Abstract
The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting.Keywords
Funding Information
- Sanofi
This publication has 16 references indexed in Scilit:
- Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetesCurrent Medical Research and Opinion, 2018
- Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysisEndocrine, 2017
- A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulinDiabetes/Metabolism Research and Reviews, 2016
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized TrialDiabetes Care, 2016
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialDiabetes Care, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized TrialDiabetes Care, 2016
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeNew England Journal of Medicine, 2015
- Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the dayJournal of Diabetes and its Complications, 2014
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008